Clinical Need & Applications
Breast conserving surgery – conflicting goals
According to a world-renowned breast cancer surgeon at a Boston hospital, "Clean margins are the number one issue for breast cancer surgery and breast conserving lumpectomies."
Balancing the need to ensure you’ve removed cancerous tissue and tumor margins while preserving precious tissue is a perpetual challenge. Despite standardization of negative margin definition, applications of new technologies, and promising new surgical techniques, this still represents a significant unmet need for surgeons and patients.
“Re-excision rates among women with close or positive margins range from less than 10% to more than 50%, and the burdens of reoperation (cosmetic, emotional, and financial) are considerable.” [NEJM 2015]
The Lumicell Margin Assessment System (MAS) is an investigational contrast agent (LUM015) and handheld illumination device combination that enables surgeons to see residual cancer cells in the cavity walls in real-time during surgery. The Lumicell MAS is designed to ensure complete clearance of cancer cells while sparing healthy tissue, increasing physician and patient confidence in surgical and cosmetic outcomes.
Lumicell MAS is also under investigation for colorectal cancer, Barrett’s esophagus and brain metastases.